SEC ownership of Indivior Pharmaceuticals, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001625297.

Comparable stake leader

BlackRock, Inc.

Disclosed value leader

BlackRock, Inc.

Comparable rows

23/50

Latest evidence

22 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
23 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
22 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001625297
Issuer location
North Chesterfield, VA

Ownership snapshot

Top shareholders of Indivior Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
23/50
Latest evidence
22 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 14% 27 rows are not safely comparable across share classes. 13D/G row: BlackRock, Inc. Showing 1-8 of 50 holder rows.

Quick read

BlackRock, Inc. leads the comparable SEC ownership view at 14%.

23 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership Top 5
BlackRock, Inc. 14%
VANGUARD PORTFOLIO MANAGEMENT LLC 6.6%
Oaktree Capital Holdings, LLC 5.7%
VANGUARD CAPITAL MANAGEMENT LLC 5.4%
Two Seas Capital LP 5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock, Inc.
13D/G 13F
Company
14%
$638,884,065
17,806,183 shares
+$335,082,637 31 Dec 2025
VANGUARD PORTFOLIO MANAGEMENT LLC
13D/G 13F
Vanguard Portfolio Management · Company
6.6%
$272,463,211
7,994,836 shares
$0 31 Mar 2026
Oaktree Capital Holdings, LLC
13D/G
5.7%
$232,808,746
7,108,664 shares
-$53,592,755 24 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC
13D/G 13F
Vanguard Capital Management · Company
5.4%
$222,327,725
6,523,720 shares
$0 31 Mar 2026
Two Seas Capital LP
13D/G 13F
Company
5%
$203,438,218
6,211,854 shares
-$27,837,500 23 Dec 2025
MILLENNIUM MANAGEMENT LLC
13D/G 13F
Company
3.8%
$158,472,151
4,806,556 shares
+$77,320,782 17 Mar 2026
FULLER & THALER ASSET MANAGEMENT, INC.
13D/G 13F
Company
3.7%
$146,214,501
4,529,583 shares
-$59,457,962 31 Mar 2026
James E. Flynn
13D/G
Deerfield Mgmt, L.P.
3.7%
$111,255,547
4,614,498 shares
-$143,518,681 10 Nov 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$1,860,975.

Buys
$203,608
Insiders: 6
Sells
$2,064,583
Insiders: 2
Net
-$1,860,975
Shares: -48,736
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 5,850 Shares: 54,586
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 54,586 $0 $2,064,583 -$2,064,583
3-6 979 0 $31,211 $0 +$31,211
6-9 4,871 0 $172,397 $0 +$172,397
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-13 of 13 reporting-owner rows connected to Indivior Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
13
Largest Forms 3/4/5 holder
Joseph Ciaffoni
Net 12M change
-$1,860,976
Latest report
22 Jun 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Joseph Ciaffoni Chief Executive Officer, Director $24,089,258 Mixed 22 Jun 2026
Ryan Preblick Chief Financial Officer $10,735,112 -$1,357,200 -11% Filing P/S 08 Jun 2026
Christian Heidbreder Chief Scientific Officer $8,674,749 -$707,383 -7.5% Filing P/S 11 Jun 2026
Jeffrey W. Burris Chief Legal Officer $2,357,948 Market 03 Mar 2026
Patrick A. Barry Chief Commercial Officer $1,066,920 Mixed 10 Feb 2026
David E. Wheadon Director $993,575 +$62,680 +6.7% Mixed 13 May 2026
Daniel A. Ninivaggi Director $876,818 +$27,429 +3.2% Mixed 13 May 2026
Mark Stejbach Director $874,365 +$27,429 +3.2% Mixed 13 May 2026
Woodrow D. Anderson Chief Accounting Officer $812,314 Market 03 Mar 2026
Juliet Thompson Director $605,183 Mixed 12 May 2026
Keith Humphreys Director $517,834 +$27,429 +5.6% Mixed 13 May 2026
Barbara Ryan Director $395,170 +$28,687 +7.8% Mixed 13 May 2026
Stuart A. Kingsley Director $390,586 +$29,953 +8.3% Mixed 13 May 2026

Recent insider transactions for Indivior Pharmaceuticals, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Joseph Ciaffoni INDV Common Stock Tax liability -43.7% -612,549 790,330 22 Jun 2026 Direct
Joseph Ciaffoni INDV Common Stock Options Exercise 931.7% 1,266,903 1,402,879 22 Jun 2026 Direct
Joseph Ciaffoni INDV Performance Stock Units Options Exercise -100% -1,266,903 0 22 Jun 2026 Direct
Christian Heidbreder INDV Common Stock Sale -7.54% $707,383 $38.06 -18,586 227,923 11 Jun 2026 Direct
Ryan Preblick INDV Common Stock Sale -11.2% $1,357,200 $37.70 -36,000 284,751 08 Jun 2026 Direct
Juliet Thompson INDV Common Stock Award 101% 6,518 12,973 13 May 2026 Direct
Keith Humphreys INDV Common Stock Award 68.4% 6,518 16,042 13 May 2026 Direct
Stuart A. Kingsley INDV Common Stock Award 116.8% 6,518 12,100 13 May 2026 Direct
Daniel A. Ninivaggi INDV Common Stock Award 31.6% 6,518 27,163 13 May 2026 Direct
Barbara Ryan INDV Common Stock Award 113.9% 6,518 12,242 13 May 2026 Direct
Mark Stejbach INDV Common Stock Award 31.7% 6,518 27,087 13 May 2026 Direct
David E. Wheadon INDV Common Stock Award 51.2% 10,430 30,780 13 May 2026 Direct
Juliet Thompson INDV Common Stock Tax liability -14.8% -1,117 6,455 12 May 2026 Direct
Ryan Preblick INDV Common Stock Tax liability -0.88% -2,843 320,751 14 Mar 2026 Direct
Ryan Preblick INDV Common Stock Options Exercise 1.99% 6,302 323,594 14 Mar 2026 Direct
Ryan Preblick INDV Restricted Stock Units Options Exercise -100% -6,302 0 14 Mar 2026 Direct
Barbara Ryan INDV Common Stock Purchase 0.14% $249 $31.08 8 5,724 13 Mar 2026 Direct
Barbara Ryan INDV Common Stock Purchase 0.55% $1,009 $32.56 31 5,716 09 Mar 2026 Direct
Stuart A. Kingsley INDV Common Stock Purchase 20.2% $29,953 $31.86 940 5,582 06 Mar 2026 Direct
Woodrow D. Anderson INDV Common Stock Tax liability -33.9% -10,965 21,374 03 Mar 2026 Direct
Woodrow D. Anderson INDV Common Stock Options Exercise 454.6% 24,310 29,657 03 Mar 2026 Direct
Woodrow D. Anderson INDV Restricted Stock Units Options Exercise -100% -5,946 0 03 Mar 2026 Direct
Woodrow D. Anderson INDV Performance Stock Units Options Exercise -100% -23,975 0 03 Mar 2026 Direct
Ryan Preblick INDV Common Stock Options Exercise 37.8% 86,949 317,292 03 Mar 2026 Direct
Ryan Preblick INDV Common Stock Tax liability -27.6% -87,597 230,343 03 Mar 2026 Direct
Ryan Preblick INDV Performance Stock Units Options Exercise -100% -113,510 0 03 Mar 2026 Direct
Jeffrey W. Burris INDV Common Stock Tax liability -33.5% -36,032 71,518 03 Mar 2026 Direct
Jeffrey W. Burris INDV Common Stock Options Exercise 288.9% 79,893 107,550 03 Mar 2026 Direct
Jeffrey W. Burris INDV Performance Stock Units Options Exercise -100% -104,300 0 03 Mar 2026 Direct
Christian Heidbreder INDV Common Stock Tax liability -15.7% -45,797 246,509 03 Mar 2026 Direct
Christian Heidbreder INDV Common Stock Options Exercise 53.2% 101,544 292,306 03 Mar 2026 Direct
Christian Heidbreder INDV Performance Stock Units Options Exercise -100% -132,565 0 03 Mar 2026 Direct
Woodrow D. Anderson INDV Common Stock Award 157.2% 6,903 11,293 10 Feb 2026 Direct
Ryan Preblick INDV Common Stock Award 13.3% 37,358 317,940 10 Feb 2026 Direct
Jeffrey W. Burris INDV Common Stock Award 3539.1% 26,897 27,657 10 Feb 2026 Direct
Christian Heidbreder INDV Common Stock Award 21.4% 33,622 190,762 10 Feb 2026 Direct
Patrick A. Barry INDV Common Stock Award 31,380 31,380 10 Feb 2026 Direct
Joseph Ciaffoni INDV Common Stock Award 142.8% 79,976 135,976 10 Feb 2026 Direct
Woodrow D. Anderson INDV Performance Stock Units Award 23,975 23,975 09 Feb 2026 Direct
Ryan Preblick INDV Performance Stock Units Award 113,510 113,510 09 Feb 2026 Direct
Jeffrey W. Burris INDV Performance Stock Units Award 104,300 104,300 09 Feb 2026 Direct
Christian Heidbreder INDV Performance Stock Units Award 132,565 132,565 09 Feb 2026 Direct
Keith Humphreys INDV Common Stock Award 64.2% 3,722 9,524 26 Jan 2026 Direct
Barbara Ryan INDV Common Stock Award 189.6% 3,722 5,685 26 Jan 2026 Direct
David E. Wheadon INDV Common Stock Award 41.4% 5,955 20,350 26 Jan 2026 Direct
Juliet Thompson INDV Common Stock Award 96.7% 3,722 7,572 26 Jan 2026 Direct
Mark Stejbach INDV Common Stock Award 22.1% 3,722 20,569 26 Jan 2026 Direct
Stuart A. Kingsley INDV Common Stock Award 404.6% 3,722 4,642 26 Jan 2026 Direct
Daniel A. Ninivaggi INDV Common Stock Award 22% 3,722 20,645 26 Jan 2026 Direct
Barbara Ryan INDV Ordinary Shares Purchase 65.2% $27,429 $35.39 775 1,963 05 Jan 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .